Apimeds Pharmaceuticals US (APUS) Assets (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Assets for 4 consecutive years, with $127.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets rose 1110.08% year-over-year to $127.6 million; the trailing twelve-month figure through Jun 2026 stood at $127.6 million (up 1110.08% YoY), and the FY2025 full-year result was $164.2 million, up 1257338.43% from the prior year.
• Assets slipped to $127.6 million in Q2 2026 per APUS's latest filing, from $164.2 million in the prior quarter.
• Across five years, Assets topped out at $164.2 million in Q4 2025 and bottomed at $13057.0 in Q4 2024.
• Historically, Assets has averaged $44.6 million across 4 years, with a median of $9.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Assets slumped 96.91% in 2024, then soared 1257338.43% in 2025.
• Over 4 years, Assets stood at $422076.0 in 2023, then plunged by 96.91% to $13057.0 in 2024, then jumped by 1257338.43% to $164.2 million in 2025, then decreased by 22.27% to $127.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $127.6 million, $164.2 million, and $9.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.